Vitamin E-loaded dialyzer resets PBMC-operated cytokine network in dialysis patients

Kidney International

Volumn 65, Issue 4, 2004, Pages 1473-1481

  Libetta, Carmelo ^a   Zucchi, Manuela ^b   Gori, Elena ^b   Sepe, Vincenzo ^b   Galli, Francesco ^b   Meloni, Federica ^b   Milanesi, Fabio ^b   Dal Canton, Antonio ^b  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b NONE

Author keywords

Biocompatibility; Cytokines; Hemodialysis; Nitric oxide; Th lymphocytes; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; CD4 ANTIGEN; CYTOKINE; DIALYSIS FLUID; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 4; REACTIVE OXYGEN METABOLITE; RETINOL;

ADULT; AGED; ANTIOXIDANT ACTIVITY; ARTICLE; ARTIFICIAL KIDNEY; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; FEMALE; HEMODIALYSIS; HUMAN; LYMPHOCYTE DIFFERENTIATION; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL; VITAMIN BLOOD LEVEL;

EID: 1642504334     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2004.00528.x     Document Type: Article

References (41)

1. KELLY CJ: T cell function in chronic renal failure and dialysis. Blood Purif 12:36-41, 1994
2. RASKA K, RASKOVA J, SHEA SM, et al: T cell subsets and cellular immunity in end-stage renal disease. Am J Med 75:734-740, 1983
3. LIBETTA C, RAMPINO T, DAL CANTON A: Polarization of T-helper lymphocytes toward the Th2 phenotype in uremic patients. Am J Kidney Dis 31:848-852, 2001
4. TORRES Y, MEDRANO FJ, REY C, et al: Evidence for a role of T-helper type 2 cytokines in the acquisition of human immunodeficiency virus syncytium-inducing phenotype. Eur J Clin Invest 28:930-936, 1998
5. DIAZ-MITOMA F, KUMAR A, KARIMI S, et al: Expression of IL-10, IL-4 and interferon-gamma in unstimulated and mitogen-stimulated peripheral blood lymphocytes from HIV-seropositive patients. Clin Exp Immunol 102:31-39, 1995
6. LIANG B, ARDESTANI S, MARCHALONIS JJ, WATSON RR: T-cell-receptor dose and the time of treatment during murine retrovirus infection for maintenance of immune function. Immunology 87:198-204, 1996
7. BIRON C, GAZZINELLI RT: Effects of IL-12 on immune responses to microbial infections: A key mediator in regulating disease outcome. Curr Opin Immunol 7:485-496, 1995
8. BEAURAIN G, NARET C, MARCON L, et al: In vivo T cell preactivation in chronic uremic hemodialyzed and non-hemodialyzed patients. Kidney Int 36:636-644, 1989
9. MEMOLI B, LIBETTA C, DE NICOLA L, et al: Hemodialysis related interleukin-2 receptor release by peripheral blood mononuclear cells. ASAIO J 42:60-63, 1996
10. ZAOUI P, GREEN W, HAKIM RM: Hemodialysis with cuprophane membrane modulates interleukin-2 receptor expression. Kidney Int 39:1020-1026, 1991
11. BEAURAIN G, NARET C, MARCON L, et al: In vivo T cell preactivation in chronic uremic hemodialyzed and non-hemodialyzed patients. Kidney Int 36:636-644, 1989
12. GAZZINELLI RT, HIENY S, WYNN TA, et al: Interleukin-12 is required for the T-lymphocyte-independent induction of interferon gamma by an intracellular parasite and induces resistance in T-cell-deficient host. Proc Natl Acad Sci USA 90:6115-6119, 1993
13. TRINCHIERI G: Interleukin-12 and its role in the generation of TH1 cells. Immunol Today 14:335-339, 1993
14. MARCHANT A, BRUYNS C, VANDENABEELE P, et al: Interleukin-10 controls interferon-gamma and tumor necrosis factor production during experimental endotoxemia. Eur J Immunol 24:1167-1171, 1994
15. OKAMURA H, TSUTSUI H, KOMATSU T, et al: Cloning a new cytokine that induces IFN-gamma production by T cells. Nature 378:88-91, 1995
16. DINARELLO CA, NOVICK D, RUBINSTEIN M, LONNEMANN G: Interleukin 18 and interleukin 18 binding protein: Possible role in immunosuppression of chronic renal failure. Blood Purif 21:258-70, 2003
17. NAKANISHI K, YOSHIMOTO T, TSUTSUI H, OKAMURA H: Interleukin-18 regulates both Th1 and Th2 responses. Annu Rev Immunol 19:423-474, 2001
18. ISHIZUKA T, NITTA K, YOKOYAMA T, et al: Increased serum levels of interleukin-12 may be associated with Th1 differentiation in hemodialysis patients. Nephron 90:503-4, 2002
19. GALLI F, ROVIDATI S, CHIARANTINI L, et al: Bioreactivity and biocompatibility of a vitamin E-modified multi-layer hemodialysis filter. Kidney Int 54:580-589, 1998
20. GALLI F, RONCO C: Oxidant stress in hemodialysis. Nephron 84:1-5, 2000
21. BAEUERLE PA, HENKEL T: Function and activation of NFkb in the immune system. Ann Rev Immunol 12:141-179, 1994
22. THOMAS CE, JACKSON RL, OHLWEILER DF, KU G: Multiple lipid oxidation products in LDL induce IL-1β release from human blood mononuclear cells. J Lipid Res 35:417-427, 1994
23. DEVARAJ S, LI D, JIALAL I: The effects of alpha tocopherol supplementation on monocyte function. J Clin Invest 98:756-763, 1996
24. MEYDANI M: VITAMIN E. Lancet 345:170-175, 1995
25. MCCAY PB, KING MM: VITAMIN E: Its role as a biological free radical scavenger and its relationship to the microsomial mixed function oxidase system, in Vitamin E: A Comprehensive Treatise, edited by Machalin LJ, New York, Marcel Dekker, Inc., 1980, pp 289-298
26. LOCATELLI F, CANAUD B, ECKARDT KU, ZOCCALI C: Oxidative stress in end-stage renal disease: An emerging threat to patient outcome. Nephrol Dial Transplant 18:1272-1280, 2003
27. GALLI F, ROVIDATI S, BENEDETTI S, et al: Lipid peroxidation, leukocyte function and apoptosis in HD patients treated with vitamin E-modified filters. Contrib Nephrol 127:156-171, 1999
28. GALLI F, VARGA Z, BALLA J, et al: Vitamin E, lipid profile, and peroxidation in hemodialysis patients. Kidney Int 59(Suppl 78):S148-S154, 2001
29. USBERTI M, GERARDI G, BUFANO G, et al: Effects of erythropoietin and vitamin E-modified membrane on plasma oxidative stress markers and anemia of hemodialyzed patients. Am J Kidney Dis 40:590-599, 2002
30. SATOH M, YAMASAKI Y, NAGAKE Y, et al: Oxidative stress is reduced by the long-term use of vitamin E-coated dialysis filters. Kidney Int 59:1943-1950, 2001
31. LIBETTA C, DE NICOLA L, RAMPINO T, et al: Inflammatory effects of peritoneal dialysis: Evidence of systemic monocyte activation. Kidney Int 49:506-511, 1996
32. HORL WH: Hemodialysis membranes: Interleukins, biocompatibility, and middle molecules. J Am Soc Nephrol 13(Suppl 1):S62-S71, 2002
33. GIRNDT M, LENGLER S, KAUL H, et al: Prospective crossover trial of the influence of vitamin E-coated dialyzer membranes on T-cell activation and cytokine induction. Am J Kidney Dis 35:95-104, 2000
34. RAMPINO T, LIBETTA C, DE SIMONE W, et al: Hemodialysis stimulates hepatocyte growth factor release. Kidney Int 53:1382-1388, 1998
35. LIBETTA C, RAMPINO T, PALUMBO G, et al: Circulating serum lectins of patients with IgA nephropathy stimulate IL-6 release from mesangial cells. J Am Soc Nephrol 8:208-213, 1997
36. KELLY FJ, RODGERS W, HANDEL J, et al: Time course of vitamin E repletion in the premature infant. Br J Nutr 63:631-8, 1990
37. DESCAMPS-LATSCHA B, HERBELIN A, NGUYEN AT, et al: Balance between IL-1 beta, TNF alpha, and their specific inhibitors in chronic renal failure and maintenance dialysis. Relationship with activation markers of T cells, B cells and monocytes. J Immunol 15:882-892, 1995
38. PEREIRA BJ: Cytokine production in patients on dialysis. Blood Purif 13:135-146, 1995
39. MEMOLI B, LIBETTA C, RAMPINO T, et al: Hemodialysis related induction of interleukin-6 production by blood mononuclear cells. Kidney Int 42:320-326, 1992
40. BADIOU S, CRISTOL JP, MORENA M, et al: Vitamin E supplementation increases LDL resistance to ex vivo oxidation in hemodialysis patients. Int J Vitam Nutr Res 73:290-296, 2003
41. MYDLIK M, DERZSIOVA K, RACZ O, et al: A modified dialyzer with vitamin E antioxidant defense parameters. Kidney Int 59(Suppl 78):S144-S147, 2001